GeneDx Holdings Corp Stock Price, News & Analysis

GeneDx announced the publication of peer-reviewed research from the GUARDIAN study in JAMA, examining the use of whole genome sequencing (WGS) for newborn screening. The study, aiming to enroll 100,000 newborns, found that 3.7% of 4,000 enrolled newborns had positive screenings, with 92% of true positive findings being conditions not included in traditional newborn screening. The study screened for 255 early-onset genetic conditions, including 156 with established treatments. Notable findings included conditions like Long QT syndrome, severe combined immunodeficiencies, and Wilson disease. The study showed high acceptance rates, with 72% of families consenting to participate and 90.6% opting for additional neurodevelopmental disorder screening.

GeneDx (Nasdaq: WGS), a leader in genomic insights, has conducted genomic newborn screenings (gNBS) for over 14,000 infants through research studies like GUARDIAN and Early Check. This positions GeneDx as a laboratory leader in revolutionizing newborn screening. The company's analysis shows that 21% of patients could have received diagnoses an average of 8 years earlier if gNBS had been available at birth.

Dr. Paul Kruszka, Chief Medical Officer at GeneDx, will present 'Lessons Learned: 14,000+ Infants Screened with Newborn Sequencing' at the International Conference on Newborn Sequencing (ICoNS). GeneDx's work in gNBS supports its vision of quick genetic disorder diagnosis to prevent disease progression and ensure healthier lives.

GeneDx (Nasdaq: WGS), a leader in genomic insights for improved health outcomes, has announced it will release its third quarter 2024 financial results before the market opens on Tuesday, October 29, 2024. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results.

Investors interested in participating in the conference call must register online. A live and archived webcast of the event will be available on the 'Events' section of GeneDx's investor relations website at https://ir.genedx.com/.

GeneDx specializes in rare disease diagnostics, offering exome and genome tests that translate complex genomic data into clinical answers. The company aims to provide personalized, targeted medical care through genetic diagnosis.

GeneDx (Nasdaq: WGS), a leader in genomic insights for improved health outcomes, has announced the granting of 7,700 restricted stock units (RSUs) to two newly hired employees. The grants, effective September 23, 2024, were approved by the compensation committee of GeneDx's board of directors as inducement awards under the company's 2023 Equity Inducement Plan.

The RSUs will vest in equal annual installments over four years, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement. This action aligns with Nasdaq Listing Rule 5635(c)(4), which allows for equity grants to new employees without shareholder approval.

GeneDx (Nasdaq: WGS), a leader in genomic insights, announced its participation in upcoming investor conferences. The company will attend the UBS Genomic Medicine Summit (August 13-14, 2024), Morgan Stanley Healthcare Conference (September 4-6, 2024), Wells Fargo Healthcare Conference (September 4-6, 2024), and Jefferies London Healthcare Conference (November 19-21, 2024).

GeneDx will participate in a panel discussion on the Future of Genetic Testing at the UBS summit and hold a fireside chat at the Wells Fargo conference. Select presentations will be available via webcast on the company's investor relations website. GeneDx specializes in rare disease diagnostics, offering exome and genome tests to provide personalized healthcare solutions and accelerate drug discovery.

GeneDx (Nasdaq: WGS), a leader in genomic insights for improved health outcomes, has granted 75,100 restricted stock units (RSUs) to seven newly hired employees as inducement awards. The RSUs, granted under GeneDx's 2023 Equity Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), will vest in equal annual installments over four years, subject to continued employment. Each RSU represents a right to receive one share of GeneDx's Class A Common Stock upon settlement. The company typically uses a 'sell to cover' transaction to address tax withholding obligations upon vesting and settlement of RSUs.

GeneDx (Nasdaq: WGS) has announced significant enhancements to its Whole Genome Sequencing (WGS) offering, aimed at accelerating diagnoses for patients. The improvements include:

• Faster turnaround time for Rapid WGS (rWGS), providing written results in as soon as 5 days
• Addition of buccal swab (cheek swab) sample collection option for WGS patients
• Expansion of repeat expansions covered by WGS to increase diagnostic yield

These enhancements, combined with GeneDx's extensive dataset of over 665,000 sequenced clinical exomes and genomes, are expected to improve the accessibility and effectiveness of WGS for diagnostic purposes, ultimately leading to better health outcomes for patients with rare and common diseases.

GeneDx (Nasdaq: WGS) reported strong Q2 2024 financial results, with revenue from continuing operations reaching $68.9 million, a 52% year-over-year increase. Exome and genome test revenue grew 77% to $50.7 million. Adjusted gross margin expanded to 62%, while adjusted net loss narrowed to $2.7 million. The company raised its full-year 2024 revenue guidance to $255-$265 million and reiterated its expectation to reach profitability in 2025.

Key highlights include a 52% year-over-year increase in exome and genome test volume, expanded Medicaid coverage for whole exome sequencing, and new collaborations to enhance access to rapid whole genome sequencing. GeneDx also announced reinvestment in whole genome sequencing products, improving turnaround times and sample collection methods.

GeneDx (Nasdaq: WGS) will report its financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. A conference call to discuss these results will be held at 4:30 p.m. Eastern Time on the same day. Investors can register to listen to the call online, and a live and archived webcast will be available on the GeneDx investor relations website. GeneDx specializes in genomic insights, offering exome and genome tests to enhance personalized health care and drug discovery. For more information, visit genedx.com.